Abrocitinib is one of Pfizer’s top experimental therapies, pegged by the drugmaker for several billion dollars in peak annual sales in the future.
But its fate, along with the fate of two other drugs from AbbVie and Lilly that are designed to work similarly, are tied to a months-long safety review by the Food and Drug Administration. Over the course of this year, the agency has pushed back several approval decisions on additional indications for AbbVie’s and Lilly’s drugs, respectively called Rinvoq and Olumiant, and on an initial OK for abrocitinib in atopic dermatitis, or eczema.
